Special Issue on Cannabidiol (CBD)
Though cannabidiol (CBD) has been known for over 60 years, it has risen in popularity throughout the world only recently. The FDA approval and therapeutic success of Epidiolex, which is a 99% CBD preparation, for intractable pediatric seizures illustrated that CBD is an effective drug in specific disease states. The mechanism of action of CBD, however, is still under much debate. In this special issue Cannabis and Cannabinoid Research and the International Cannabinoid Research Society are inviting the submission of all studies aimed at understanding CBD’s mechanisms of action. These studies can be aimed at understanding behavioral, physiological, cellular, or molecular outcomes of CBD treatment.
This special issue aims to provide insight into our current understanding of the field and highlight new findings. All studies on CBD will be considered for the issue. Reviews, mini-reviews, and original research articles will be considered.
We also encourage submission of papers that have been published in conference proceedings, with the requirement that the authors have made significant extensions as compared to the already published version of the study.
Reminder: International Cannabinoid Research Society, Association of Cannabis Specialists, and International Association for Cannabinoid Medicines members receive a discount off of article processing charges (APCs) if they elect to publish articles Open Access.
Deadline for manuscript submission: Dec 31, 2021
Questions or pre-submission queries? Please contact Guest Editor Dr. Heather Bradshaw at email@example.com
Access the complete instructions for authors here
Submit your manuscript online here